Key facts
- This page summarizes Eiry Roberts's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Jan 2022, 16:53.
Eiry Roberts - 10 Jan 2022 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- NBIX
- Reported as of
- 10 Jan 2022
- Net transaction value
- -$196,088
- SEC form
- 4
- Accepted by SEC
- 12 Jan 2022, 16:53:57 UTC
- Prior SEC filing
- 14 Jun 2021
- Next SEC filing
- 02 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darin Lippoldt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eiry Roberts filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 12 Jan 2022.
Change
- Previous filing in this sequence was filed on 14 Jun 2021.
- Current net transaction value: -$196,088.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NBIX
transaction
Common Stock
Sale
- Transaction value
- $196,088
- Shares
- -2,632
- Change %
- -11%
- Price
- $74.50
- Shares after
- 21,279
- Date
- 10 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 10, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Footnote F2
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $72.14 to $76.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F3
Includes an aggregate of 218 shares purchased on February 26, 2021 and August 31, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.